ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

An Interdisciplinary & Holistic Approach to Alleviating Pediatric Pain

Carina Stanton  |  July 22, 2019

Interdisciplinary collaboration is proving valuable to address bio-psycho-social pain management in pediatric patients at Children’s Hospital Los Angeles…

Filed under:Conditions

The Microbiome: A Predictor of Autoimmune Response?

Thomas R. Collins  |  July 18, 2019

CHICAGO—The world of rheumatology is beginning to harness the promise of the microbiome, with evidence showing components of the gut may help predict response to medication and may be manipulated to improve how well a treatment works, said Jose Scher, MD, at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7. “We can truly exploit…

Filed under:ConditionsResearch Rheum Tagged with:MicrobiomePrecision MedicinepredictorResearch

Expert Says Vaccines Are Largely Safe for Rheumatology Patients

Thomas R. Collins  |  July 18, 2019

CHICAGO—Rheumatologists often come to Brian Schwartz, MD, associate professor of medicine and vice chief for clinical affairs in the Division of Infectious Diseases, University of California, San Francisco, with a concern: A patient on immunosuppression has a family member who needs a live vaccine, but the patient may be vulnerable to the vaccine’s effects. Should…

Filed under:ConditionsPractice Support Tagged with:vaccinationvaccines

Andrey_Popov a/ shutterstock.com

What Attracts Us to Rheumatology? A Veteran Rheumatologist Reflects

Ronald J. Anderson, MD  |  July 18, 2019

What attracts physicians to a career in rheumatology? Traditionally, the foundation of clinical training at both the medical student and house staff level is based on inpatient services. There are many reasons for this, predominantly revolving around access to patients available for teaching. The result: Trainees are predominantly exposed to a group of conditions that…

Filed under:Professional TopicsWorkforce Tagged with:Career

David M. Phillips / Science Source

Lyme Arthritis: Presentation, Diagnosis & Treatment

John N. Aucott, MD, & Sheila L. Arvikar, MD  |  July 18, 2019

A 52-year-old man living in greater Boston with a history of hyper­tension presented at our rheumatology clinic with bilateral knee pain and swelling. He had been in his usual state of health until four months earlier when he developed right knee pain and swelling without an incipient trauma, which did not improve with non-steroidal anti-inflammatory…

Filed under:Conditions Tagged with:Borrelia burgdorferiLyme arthritisLyme Disease

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

Lara C. Pullen, PhD  |  July 10, 2019

A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:adalimumabJIAjuvenile idiopathic arthritis (JIA)Uveitis

Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Arthritis & Rheumatology  |  June 27, 2019

Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Arthritis & Rheumatologyaxial spondyloarthritis (SpA)Certolizumab PegolResearch

Coding Corner Answers: An Audit Record Request Quiz

From the College  |  June 17, 2019

Take the challenge. C—When an insurance carrier requests the medical record for a service performed, the practice should send all pertinent information to support the medical necessity of that service. For example, if the drug requires that a patient first be tested for tuberculosis and the patient should be on methotrexate or leflunomide, the note…

Filed under:From the CollegePractice Support Tagged with:Auditsprior authorizations

Biological DMARDs in Elderly RA Patients: Use, Maintenance & Discontinuation

Natasha Yetman  |  June 17, 2019

A study comparing seven biologic DMARDs in RA patients aged 65 years and older found abatacept had the highest retention rate and the lowest discontinuation rate…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptadalimumabbiologic disease-modifying antirheumatic drugsbiologic DMARDsCertolizumab PegoletanerceptGolimumabinfliximabRheumatoid Arthritis (RA)tocilizumab

The Microbiome: A Predictor of Response?

Natasha Yetman  |  June 12, 2019

New research by Jose Scher, MD, discussed during the 2019 ACR State-of-the-Art Clinical Symposium, demonstrated how clinicians may be able to modify aspects of the microbiome to predict and boost a patient’s treatment response…

Filed under:Uncategorized Tagged with:2019 State-of-the-Art Clinical Symposiumdrug treatmentMicrobiomePharmacomicrobiomics

  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences